November 21st 2024
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
October 21st 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Response to Checkpoint Inhibition in Urothelial Cancer May Be Affected by Autoimmune Events
July 2nd 2019The development of an immune-related adverse event was associated with improved patient response in an FDA analysis of patients with advanced urothelial cancer treated with a PD-1/PD-L1 inhibitor.
Read More
High Response Rate Seen With Concurrent Ibrutinib Plus CAR T-Cell Therapy in High-Risk CLL
June 26th 2019Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib. Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.
Read More
Treatment Patterns at End of Life Explored in Large, National Database
June 20th 2019The American Cancer Society, Dana-Farber Cancer Institute, Baptist Cancer Center, and the Mayo Clinic report that treatment patterns varied markedly by cancer type and care facility setting for patients with de novo metastatic disease who died within 1 month after diagnosis, based on an analysis of data from 100,848 patients collected from the National Cancer Database, a hospital-based cancer registry that captures 70% of patients in the United States with a new diagnosis.
Read More
Monitoring of ctDNA in Patients With Bladder Cancer Has Potential to Assist Therapy Selection
June 20th 2019By testing circulating tumor DNA at critical time points throughout neoadjuvant chemotherapy and cystectomy, clinicians may be able to better predict which patients with advanced bladder cancer would likely benefit from additional systemic therapies, according to results of a study published in the <em>Journal of Clinical Oncology</em>.
Read More
FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion
June 19th 2019The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.
Read More
Strategies to Engage Underrepresented Populations Improves Inclusivity in Clinical Trials
June 17th 2019A cohort of cancer centers was selected to serve as models for identifying key strategies for racial and ethnic minority group engagement in clinical trials. On the basis of several qualifying criteria, such as sustained accrual of minorities into clinical cancer research, an established minority population ≥10% in the overall catchment, an established clinical trial infrastructure, and a formal community outreach program, the investigators identified 8 cancer centers for participation.
Read More
Novel Combinations Explored in CRC With Rare Gene Mutations
June 15th 2019In a case-based-style discussion, Tanios S. Bekaii-Saab, MD, and Wells Messersmith, MD, reviewed the treatment of patients with colorectal cancer whose tumors express rare gene mutations or molecular signatures, such as <em>NTRK</em> fusions.
Read More
Ongoing Clinical Trials Aim to Avoid Cystectomies for Select Patients With Bladder Cancer
June 11th 2019In an interview with <em>Targeted Oncology</em>, Paul L. Crispen, MD, discussed several ongoing trials for patients with bladder cancer focused on the importance of bladder preservation. He also highlighted a clinical trial currently enrolling at the University of Florida Health for patients with upper tract disease.
Read More
Erdafitinib Approval in Urothelial Carcinoma Opens Door to Future Targeted Therapies
June 10th 2019The recent approval of erdafitinib has significant implications for the field, says Arjun V. Balar, MD. It marks the most recent in a string of FDA approvals in urothelial carcinoma after nearly 3 decades of little to no advancement but is, importantly, the first targeted therapy in UC, which should open the door for more biomarker-driven drug discovery.
Read More
Enfortumab Vedotin Achieves Responses in Advanced Urothelial Carcinoma
June 3rd 2019According to data from the phase II EV-201 study presented at the 2019 ASCO Annual Meeting, 44% of patients with locally advanced or metastatic urothelial cancer achieved responses with enfortumab vedotin. This includes 12% of patients reached a complete response to treatment. Median overall survival time for patients was 11.7 months.
Read More